FDA approves multiple generics of ADHD and BED treatment
Action: FDA has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients six years and older and moderate to severe binge-eating disorder (BED) in adults. See Vyvanse’s prescribing information for details on dosing.
Other Articles in this Edition
FDA approves multiple generics of ADHD and BED treatment
The 10 Unexpected ADHD Signs Most People Miss, According to Psychologists
The ADHD drug market is already stretched thin. Now it’s facing a back-to-school supply strain
For Women With Money Issues, an A.D.H.D. Diagnosis Can Be Revelatory
Pastors with ADHD Can Burn Out or Shine
Advice on recognizing and dealing with ADHD in students